Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deucravacitinib-TNFi Combination Therapy for Difficult-to-Control Psoriatic Disease
NCT07280702Phase 4Recruiting
- Sponsor
- UT Southwestern Medical Center
- Start
- Jun 2026
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of deucravacitinib in psoriatic arthritis (PsA), sponsored by UT Southwestern Medical Center. Started Jun 2026; status: recruiting.
02
Drugs
deucravacitinib
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT07280702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07280702.